1.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology：chronic myelogenous leukemia. Version 2，2018，NCCN.org.

2.Appelbaum FR，Forman SJ，Negrin RS，et al. Thomas’ Hematopoietic Cell Transplantation：Stem Cell Transplantation.4th ed. Oxford：Blackwell Publishing Ltd，2009.

3.Recommended Timing for Transplant Consultation. National Marrow Donor Program.http://www.marrow.org.

4.Xu LP，Wu DP，Han MZ，et al. A review of hematopoietic cell transplantation in China：data and trends during 2008-2016. BMT，2017，52（11）：1512-1518.

5.Xu LP，Chen H，Chen J，et al. The consensus on allogeneic hematopoietic cell transplantation for hematological diseases in China—focused on indication，conditioning regimen，and donor selection—on behalf of HSCT workgroup in Chinese Society of Hematology，Chinese Medical Association. JHO，2018.

6.Wang Y，Chang YJ，Xu LP，et al Who is the best donor for a related HLA haplotype-mismatched transplant？Blood，2014，124（6）：843-850.

7.Chang YJ，Zhao XY，Xu LP，et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation：a prospective study with randomly assigned training and validation sets. J Hematol Oncol，2015，8：84.

8.Wang Y，Wu DP，Liu QF，et al. Donor and recipient age，gender and ABO incompatibility regardless of donor source：validated criteria for donor selection for haematopoietic transplants. Leukemia，2018，32：192-498.

9.Chang YJ，Luznik L，Fuchs EJ，et al. How do we choose the best donor for T-cell-replete，HLA-haploidentical transplantation？J Hematol Oncol，2016，9：35.